<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=217082&amp;fmt=gif">
1 min read

α2-adrenergic Agonists & Tricyclic Antidepressants | Pain Model

Featured Image

α2-adrenergic receptors (α2ARs) are found in many areas in throughout the nervous system, but the α2ARs on pre- and post-synaptic neurons in the dorsal horn of the spinal cord are the main target for both endogenous and exogenous analgesia. One of the major descending inhibitory pain pathways involves the projection of noradrenergic neurons in the locus ceruleus back down to the spinal cord to activate α2ARs at this site. These receptors can also be targeted pharmacologically through administration of selective agonists or through the inhibition of noradrenaline (also known as norepinephrine) reuptake by drugs such as tricyclic antidepressants.

α2ARs are divided into three subtypes, the α2A-, α2B- and α2C-ARs. All three are Gi/o coupled GPCRs. α2AARs are expressed mostly on the central, pre-synaptic terminals of nociceptors and inhibit VGCC on these terminals to reduce the release of excitatory neurotransmitters such as glutamate and substance P. At the same time, α2CARs, expressed primarily on the second order neurons in the dorsal horn, reduce excitability of these neurons by increasing conductance through GIRK channels [1].

Tricyclic antidepressants (TCAs) are used clinically for the treatment of various neuropathic pain conditions, including nerve injury and diabetic neuropathy. Importantly, their analgesic efficacy is independent of the co-existence of depression in patients. Most TCAs have some action on both serotonin and norepinephrine reuptake, but their analgesic actions are largely mediated by increasing spinal noradrenergic tone coming from descending pathways, which then increases activation of α2ARs to produce pain relief as described above.

In accordance with their clinical usage, animal models of neuropathic pain are widely used to test novel TCAs. In fact, TCAs show little efficacy in animal models of acute or inflammatory pain. Although neuropathic and other forms of chronic pain are common indications for the clinical use of α2AR agonists as well, they show robust antinociception in a much wider variety of animal models, including acute and inflammatory ones. Also, they are used both clinically for and in animal models of postoperative pain [1].


1. Pan, H.L., et al., Modulation of pain transmission by G-protein-coupled receptors. Pharmacol Ther, 2008. 117(1): p. 141-61.